The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies,
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) September 26, 2022
✳️ 10 tweet #NephJC catch-up ✳️
Did you ever think of using acetazolamide for acute congestive heart failure?
Read on to see whether we should or we should not! pic.twitter.com/e6XHi1JouG